A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

NCT06984718 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC
Hepatocellular Carcinoma

Interventions

BIOLOGICAL: AK104+lenvatinib
DRUG: lenvatinib

Sponsor

Akeso